Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial
{{output}}
Background/objectives: Pancreatic ductal adeno carcinoma (PDAC) in its borderline resectable (BR) stage often limits the possibility of complete resection, currently the only potential path to a cure. Neoadjuvant chemotherapy see... ...
